Pacira BioSciences Divests iovera° for $70M Upfront, Focuses on Non-Opioid Pain Therapies
Event summary
- Pacira BioSciences reported $192.4M in Q2 2026 revenue, up 6% YoY.
- Divested iovera° business to Zimmer Biomet for up to $140M, receiving $73.6M upfront.
- UnitedHealthcare now provides separate reimbursement for EXPAREL across outpatient settings.
- PCRX-201 gene therapy for osteoarthritis advances with Phase 2 study enrollment underway.
The big picture
Pacira BioSciences is sharpening its focus on non-opioid pain therapies following the divestiture of its iovera° business. The move aligns with its '5x30' growth strategy, aiming to drive long-term value through innovation and high-caliber commercial partnerships. The company's continued revenue growth and advancements in its pipeline underscore its commitment to transforming patient care in the musculoskeletal pain space.
What we're watching
- Strategic Realignment
- How the divestiture of iovera° will impact Pacira's focus on innovation-driven biopharmaceuticals and its ability to drive long-term growth.
- Reimbursement Expansion
- Whether UnitedHealthcare's separate reimbursement for EXPAREL will significantly expand access and adoption of non-opioid pain management options.
- Pipeline Progress
- The pace at which PCRX-201 advances through clinical trials and its potential to become a market-leading gene therapy for osteoarthritis.
Related topics